Plain-English translation of NCT06822036 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing ARISTA™ AH, a polysaccharide-based powder that helps control bleeding, during robotic-assisted prostate cancer surgery. Half of the participants will receive the medication applied to the surgical area after the prostate is removed, while the other half will not. Researchers want to see if this treatment leads to less blood loss after surgery and helps men maintain better erectile function.
Prostate cancer surgery can sometimes cause significant bleeding and may affect a man's ability to have erections afterward. This trial is testing whether using this medication during surgery could reduce both complications and help preserve sexual function, which is important for quality of life.
You likely qualify if…
You likely don't qualify if…
You will undergo your scheduled robotic-assisted prostate cancer surgery. During the operation, you will randomly be assigned to receive either the polysaccharide powder applied to the surgical area or standard care without it. After surgery, you will have blood tests to check hemoglobin levels and follow-up visits at 3, 6, and 12 months where you'll complete questionnaires about erectile function and overall recovery.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
Germany